AC Immune (NASDAQ:ACIU) stock shot up 20% Thursday after the company reported positive interim data from a Phase 2 study of ...

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

The researchers note that, "despite the similarities, patients with these diseases have a different prognosis and do not ...

Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

reinforces the best-in-class characteristics of our clinically validated anti-a-syn active immunotherapy for the treatment of ...

AC Immune SA (ACIU) has released an update. AC Immune SA announced promising interim results from its Phase 2 trial of the ACI-7104.056 ...

A new study that aims to understand the genetics of Parkinson’s has been held up by the need for 7000 Australians without a ...

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseActive ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

While Parkinson’s disease (PD) has a large and highly generalised therapeutic ... reflecting the field’s commitment to ...

With rising demand and an ageing population, European healthcare systems are under strain. In the second article in our ...